Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
May 08, 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
Natural Plant Extraction Player, Chongqing Joywin Natural Products Co., Ltd. plans to go public in the US via a merge with a special purpose acquisition company (SPAC)with estimated valuation of $300 million
July 05, 2023 20:22 ET
|
Chongqing Joywin Natural Products Co., Ltd.
Chongqing, China, July 05, 2023 (GLOBE NEWSWIRE) -- Chongqing Joywin Natural Products Co., Ltd. (hereinafter referred to as Chongqing Joywin) is a company that focuses on extracting various natural...
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools
February 24, 2022 12:39 ET
|
InveniAI LLC
GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...
Pan-Biome Pharmaceuticals, Inc. provides update on its longevity research program: its compounds modulate inflammation, the gut microbiome, and increase lifespan of C. elegans by 30%
December 02, 2021 10:00 ET
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc., a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole
September 16, 2021 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...
Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions
June 29, 2021 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, June 29, 2021 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
June 10, 2021 16:30 ET
|
aTyr Pharma, Inc.
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are...
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET
|
InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Intravenous Immunoglobulin (IVIG) Market To Reach USD 15.67 Billion By 2026 | Reports And Data
May 28, 2019 12:38 ET
|
Reports And Data
The rapid increase in neurological disorders, increase in geriatric population, and continuous increase in the number of patients are fueling the market growth. Market Size – USD 9.43 Billion in...